GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Price-to-Free-Cash-Flow

OptimizeRx (OptimizeRx) Price-to-Free-Cash-Flow : N/A (As of Apr. 28, 2024)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Price-to-Free-Cash-Flow?

As of today (2024-04-28), OptimizeRx's share price is $10.12. OptimizeRx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.46. Hence, OptimizeRx's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for OptimizeRx's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, OptimizeRx's highest Price-to-Free-Cash-Flow Ratio was 2070.33. The lowest was 21.51. And the median was 72.57.

OPRX's Price-to-Free-Cash-Flow is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 18.3
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

OptimizeRx's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.31. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.46.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of OptimizeRx was -181.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -3.00% per year.

During the past 13 years, OptimizeRx's highest 3-Year average Free Cash Flow per Share Growth Rate was 31.80% per year. The lowest was -43.60% per year. And the median was 1.00% per year.


OptimizeRx Price-to-Free-Cash-Flow Historical Data

The historical data trend for OptimizeRx's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Price-to-Free-Cash-Flow Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4,436.43 28.72 -

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.72 42.41 109.08 864.44 -

Competitive Comparison of OptimizeRx's Price-to-Free-Cash-Flow

For the Health Information Services subindustry, OptimizeRx's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's Price-to-Free-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Price-to-Free-Cash-Flow falls into.



OptimizeRx Price-to-Free-Cash-Flow Calculation

OptimizeRx's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=10.12/-0.461
=N/A

OptimizeRx's Share Price of today is $10.12.
OptimizeRx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

OptimizeRx  (NAS:OPRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


OptimizeRx Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022